HAMBURG—The historic German port city of Hamburg is playing host to the European Society of Gene & Cell Therapy (ESGCT) conference this week. This gathering brings together leading experts in gene therapy, highlighting advancements and ongoing challenges in the field.
Key topics discussed include patient safety, access to gene therapies, and the pursuit of an HIV vaccine. Dimitrios Mougiakakos, MHBA, emphasized the risks associated with CAR T therapy, advocating for a more cautious approach to production methods. Meanwhile, Italian professor Giuliana Ferrari, PhD, shared insights from her research on beta-thalassemia, illustrating the balance between innovation and patient outcomes, as some trial participants resumed transfusions while others achieved independence.
In a notable presentation, Bill Schief, PhD, from Moderna, outlined his team’s efforts towards developing a functional HIV vaccine, addressing the urgent need amidst declining global funding for AIDS research. Schief’s innovative strategies aim to elicit broadly neutralizing antibodies, a critical component for effective vaccination. Additionally, Michel Sadelain, MD, PhD, discussed the promise of CAR T therapy, noting significant advancements in oncology while also addressing the challenges in treating solid tumors. The conference serves as a vital platform for collaboration and knowledge exchange among professionals dedicated to advancing gene therapy.
Get started today with Solo access →
